{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.7","upperLimit":"244.0","value":"132.7"},{"groupId":"OG001","lowerLimit":"41.9","upperLimit":"69.0","value":"46.8"},{"groupId":"OG002","lowerLimit":"21.1","upperLimit":"73.9","value":"44.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"29"}],"units":"Participants"}],"description":"Carboxyethylphosphoramide mustard (CEPM) plasma concentration-time data are collected in consolidation cycle 2. Individual estimates of CEPM AUC0-24h (area under concentration curve from time 0 to 24 hours post- dose) are obtained using post hoc analysis.","dispersionType":"Full Range","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic histology, or high grade glioma","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with no evidence of metastatic disease (M0) medulloblastoma or nodular desmoplastic histology with less than a gross total resection (GTR), other histologic diagnoses with no metastatic disease","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"MEDIAN","populationDescription":"Eligible patients who received cyclophosphamide during consolidation cycle 2 and had samples collected for PK analysis.","reportingStatus":"POSTED","timeFrame":"Pre-infusion, end of infusion, 3, 6, and 24 hours from end of cyclophosphamide infusion","title":"CEPM AUC0-24h in Consolidation Chemotherapy Cycle 2","type":"SECONDARY","unitOfMeasure":"µmol·h/L"}